About us
Research Library
Company Pages
Allergy Therapeutics
ANGLE
Arecor Therapeutics
Avacta
Futura Medical
HUTCHMED
MaxCyte
Redx Pharma
Scancell
Contact us
More Company News
Arecor Therapeutics
FY22 results
16 Mar 2023
Read More
Arecor Therapeutics
Statement re: Jounce Therapeutics press release
15 Mar 2023
Read More
Arecor Therapeutics
Closing of fruquintinib licence to Takeda outside China
14 Mar 2023
Read More
Arecor Therapeutics
MED3000 commercial and US regulatory update
14 Mar 2023
Read More
Arecor Therapeutics
RXC004 topline data from a Phase II monotherapy module
08 Mar 2023
Read More
Arecor Therapeutics
Preliminary Q422 & FY22 revenue
07 Mar 2023
Read More
Arecor Therapeutics
FY22 results
28 Feb 2023
Read More
Arecor Therapeutics
Completion of enrolment in amidizalisib China Phase II registration trial in FL
27 Feb 2023
Read More
Arecor Therapeutics
Recommended business combination with Jounce Therapeutics
23 Feb 2023
Read More
Arecor Therapeutics
Encouraging early efficacy data from ModiFY trial
21 Feb 2023
Read More
1
2
3
4
…
56
Return to Arecor Therapeutics
© 2019-22 Trinity Delta. All rights reserved. Trinity Delta is regulated by the Financial Conduct Authority (Reference number: 725161).
About us
Research Library
Company Pages
▼
Allergy Therapeutics
ANGLE
Arecor Therapeutics
Avacta
Futura Medical
HUTCHMED
MaxCyte
Redx Pharma
Scancell
Contact us